Artiva Biotherapeutics Reports Q2 2026 Results in Press Release

What Happened
Artiva Biotherapeutics, Inc. announced its financial results for the quarter ended June 30, 2026 by issuing a press release on August 6, 2026. The company filed an 8‑K (Item 2.02) to disclose the results of operations and financial condition; the press release is attached to the filing as Exhibit 99.1.

Key Details

• Filing date: August 6, 2026 (Form 8-K).
• Period reported: quarter ended June 30, 2026 (Q2 2026).
• Disclosure type: Item 2.02 — Results of Operations and Financial Condition; press release attached as Exhibit 99.1.
• Administrative: Cover page interactive data (Inline XBRL) included (Exhibit 104); 8‑K signed by CEO Fred Aslan, M.D.

Why It Matters
This 8‑K signals Artiva has released its latest quarterly earnings and related financial information, which can affect stock performance and investor decisions. The 8‑K itself references the press release but does not restate financial figures in the filing text; investors should read Exhibit 99.1 for revenue, earnings/losses, cash position, guidance and any operational updates or program milestones.